Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 27:8:767064.
doi: 10.3389/fcvm.2021.767064. eCollection 2021.

miR-21 in Human Cardiomyopathies

Surina Surina  1 , Rosaria Anna Fontanella  1 , Lucia Scisciola  1 , Raffaele Marfella  1   2 , Giuseppe Paolisso  1   2 , Michelangela Barbieri  1
Affiliations
Review

miR-21 in Human Cardiomyopathies

Surina Surina et al. Front Cardiovasc Med. .

Erratum in

  • Corrigendum: miR-21 in Human Cardiomyopathies.
    Surina, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. Surina, et al. Front Cardiovasc Med. 2022 Apr 25;9:913429. doi: 10.3389/fcvm.2022.913429. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35548429 Free PMC article.

Abstract

miR-21 is a 22-nucleotide long microRNA that matches target mRNAs in a complementary base pairing fashion and regulates gene expression by repressing or degrading target mRNAs. miR-21 is involved in various cardiomyopathies, including heart failure, dilated cardiomyopathy, myocardial infarction, and diabetic cardiomyopathy. Expression levels of miR-21 notably change in both heart and circulation and provide cardiac protection after heart injury. In the meantime, miR-21 also tightly links to cardiac dysfunctions such as cardiac hypertrophy and fibrosis. This review focuses on the miR-21 expression pattern and its functions in diseased-heart and further discusses the feasibility of miR-21 as a biomarker and therapeutic target in cardiomyopathies.

Keywords: biomarkers; cardiomyopathies; fibrosis; miR-21; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The roles of miR-21 in cardiomyopathies and targeted therapy. This figure is created with BioRender.com.
Figure 2
Figure 2
Molecular mechanisms of miR-21 involvement in cardiomyopathies. Cardiomyopathy alters miR-21 expression level in heart and circulation. miR-21 has protective effects on heart in cardiomyopathy. It regulates cardiac cell death by targeting PTEN and PDCD4. There is a positive promotion loop between miR-21 and AP-1. Overexpression of miR-21 inhibits PDCD4, and further increases AP-1, which is a transcription factor directly promotes miR-21 expression. PTEN downregulation activates PI3K/Akt pathway to promote cardiomyocytes survival and proliferation, that can protect against heart dysfunction. In the meantime, miR-21 has also negative effects on cardiac diseases' development. miR-21 regulates smad7/smad2/3 and Spry/ERK pathways to promote cardiac fibrosis by increasing collagens deposition, TGFβ1, α-smooth muscle actin (α-SMA) and filamentous actin (F-actin) polymerization. Spry/ERK/mTOR pathway contributes to myocardial hypertrophy through increasing myofibroblast survival. Collagen type I/III (COL1/3), PTEN, Phosphoinositide 3-kinases (PI3K), Protein kinase B(Akt), B-cell lymphoma 2 (Bcl-2), bcl-2-like protein 4 (Bax), Programmed Cell Death 4 (PDCD4), Activator protein 1(AP-1), Extracellular signal-regulated kinase (ERK), Sprouty 1/2(Spry 1/2), Mammalian target of rapamycin (mTOR), SMAD Specific E3 Ubiquitin Protein Ligase 2 (Smurf 2), Smad anchor for receptor activation (SARA), SMAD Family Member 2/3/4/7 (Smad2/3/4/7), Filamentous actin (F-actin), Alpha smooth muscle actin (α-SMA). This figure is created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schaufelberger M. Cardiomyopathy and pregnancy. Heart. (2019)105:1543–1551. 10.1136/heartjnl-2018-313476 - DOI - PMC - PubMed
    1. Bartel DP. Metazoan microRNAs. Cell. (2018)173:20–51. 10.1016/j.cell.2018.03.006 - DOI - PMC - PubMed
    1. Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular development. Circ Res. (2009)104:724–32. 10.1161/CIRCRESAHA.108.192872 - DOI - PMC - PubMed
    1. Kan C, Cao J, Hou J, Jing X, Zhu Y, Zhang J, et al. . Correlation of miR-21 and BNP with pregnancy-induced hypertension complicated with heart failure and the diagnostic value. Exp Ther Med. (2019)17:3129–35. 10.3892/etm.2019.7286 - DOI - PMC - PubMed
    1. Zhang Y, Liu YJ, Liu T, Zhang H, Yang SJ. Plasma microRNA-21 is a potential diagnostic biomarker of acute myocardial infarction. Eur Rev Med Pharmacol Sci. (2016)20:323–9. - PubMed

LinkOut - more resources